New antibiotic active against MRSA and anthrax discovered as potential broad-spectrum therapeutic agent
Baulamycin is one of a new class of compounds extracted from marine microorganisms collected by David Shermans team in Costa Rica.

David Sherman of the Life Sciences Institute found that a new class of compounds extracted from marine microorganisms from Costa Rica's eastern Pacific waters decreased the virulence of both MRSA and anthrax. The compounds were discovered after Sherman screened the CCG's library of natural products derived from Costa Rica, Panama and Papua New Guinea.     


"We went after a target based on highly potent virulence factors--siderophores," Sherman said. "We first knocked out the genes responsible for making these iron-binding substances, and once we knew which genes those were, we had our critical drug target. With that information, we screened for molecules that could inhibit that target and stop the production of the virulence factors."   


Baulamycins A and B, broad-spectrum antibiotics identified as inhibitors of siderophore biosynthesis in Staphylococcus aureus and Bacillus anthracis (Journal of the American Chemical Society)



The Role of HTS in Drug Discovery at the University of Michigan

CCG leadership recently published an overview of drug discovery at U-M. "The primary objective of the CCG is to assist biomedical researchers in identifying small molecules, genes or natural products for drug and probe discovery. This is early drug discovery as it can provide target validation, lead compounds, and/or probes," they wrote.

The Role of HTS in Drug Discovery at the University of Michigan, Combinatorial Chemistry & High Throughput Screening (Combinatorial Chemistry & High Throughput Screening) 

The CCG compound libraries were selected for their uniqueness, structural diversity,  availability of neat sample for rapid follow up, and computed structural properties such as molecular weight, logP, polar surface area, number of rotatable bonds, and the presence of reactive or toxic structural motifs; structural properties which affect the lead-like quality of a compound.




Sigma Life Science's Library of Pharmacologically Active Compounds (LOPAC1280) is a biologically annotated collection of inhibitors, receptor ligands, pharma-developed tools, and approved drugs impacts most signaling pathways and covers all major drug target classes.



The Prestwick Chemical Library contains 1,280 small molecules that are approved drugs. The active compounds were selected for their high chemical and pharmacological diversity as well as for their known bioavailability and safety in humans.



Microsource 2400

The SPECTRUM Collection was complied by medicinal chemists and biologists to provide a wide range of biological activities and structural diversity for screening programs with special emphasis on the de novo assays.


NIH Clinical Collections

The NIH Clinical Collection and NIH Clinical Collection 2 are plated arrays of 446 and 281, respectively, small molecules that have a history of use in human clinical trials. The collection was assembled by the National Institutes of Health (NIH) through the Molecular Libraries Roadmap Initiative as part of its mission to enable the use of compound screens in biomedical research.


Natural Product Extract (NPE)

The CCG's unique natural product extract library assembled by the lab of David Sherman now contains more than 33,000 samples in 384-well plates.


CDNM pilot grant for advancing drug discovery

The Center for the Discovery of New Medicines (CDNM) announces the availability of pilot funds up to $50,000 for projects focused on drug discovery.

Preference will be given to studies on novel drug targets, clear medical need, and potential for external funding and/or translation. Successful projects will also provide a clear plan for intellectual property protection.
It is anticipated that a great majority of funds will be deployed in the component laboratories of the CDNM on behalf of the applicant.

All faculty members (instructional, clinical, and research track) employed by the University of Michigan are eligible to submit applications.


Deadline: 11:59 p.m. July 1, 2014

Criteria and details for submission


Other funding opportunities

Contact the CCG for information about available  

support from the following resources: 


The CCG website includes an updated list of grant opportunities 


About the CCG


The Center for Chemical Genomics 

(CCG) provides expertise and resources  

for University of Michigan researchers 

and others to use modern high-throughput screening (HTS) approaches in tackling 

basic biology or novel drug discovery 

projects. The CCG is housed in the Life Sciences Institute.  




Facebook    Twitter    LinkedIn    Pinterest